Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* PsA diagnosis of at least 3 months duration prior to the date of first screening with ClASsification of Psoriatic ARthritis (CASPAR) confirmed diagnosis at Screening.~* Have active psoriasis defined by at least 1 psoriasis lesion \>= 2 cm diameter in areas other than the axilla or groin.~* Have active arthritis defined by minimum disease activity criteria:~  1. \>= 3 swollen joints (based on 66 joint counts) at Screening~ 2. \>= 3 tender joints (based on 68 joint counts) at Screening~* On a stable dose of methotrexate (MTX) defined as:~  1. Oral or parenteral treatment \>= 3 months~ 2. On a stable dose with an unchanged mode of application for at least 4 weeks prior to baseline~ 3. Stable MTX dose of \>= 10 mg/week and \<= the upper limit of the applicable approved local label~ 4. Can also be on stable doses of nonsteroidal anti-inflammatory drugs, sulfasalazine and/or hydroxychloroquine as long as they are also on methotrexate~Exclusion Criteria:~* Up to 30% (approximately 66 subjects) with prior exposure to a TNF inhibitor may be enrolled if the TNF inhibitor was not discontinued due to lack of efficacy or safety concerns. Subjects must be washed out for at least 5 half-lives of these drugs prior to the Baseline visit.~* Subjects on prior adalimumab may not be enrolled in the study~* Prior exposure to other non-TNF inhibitor biological disease-modifying antirheumatic drugs (DMARDs) will be permitted if the subject is washed out at least 5 half-lives of these drugs prior to the baseline visit.~* Current treatment with traditional oral/intramuscular DMARDs, including conventional synthetic DMARDs (csDMARDs; except for concomitant treatment with sulfasalazine and/or hydroxychloroquine in addition to MTX). Oral DMARDs must be washed out for at least 5 half-lives of a drug apart from MTX prior to the Baseline visit.~  a. Subject could have been exposed to prior Janus kinase (JAK) or phosphodiesterase type 4 (PDE4) inhibitors so long as they have been off therapy for at least 5 half-lives.~* Stable prescribed dose of oral prednisone or prednisone equivalent \> 10 mg/day within the 30 days of the Baseline visit.~* Intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks of the Baseline visit. Inhaled corticosteroids for stable medical conditions are allowed.~* Laboratory values of the following at the Screening Visit:~  1. Confirmed hemoglobin \< 9 g/dL for males and \< 8.5 g/dL for females~ 2. Absolute neutrophil count (ANC) \< 1500 mm\^3, (or \< 1200 cells/µL for subjects of African descent who are black)~ 3. Aspartate aminotransferase or alanine aminotransferase \> 1.5 x the upper limit of normal (ULN) or bilirubin \>= 3 mg/dL~ 4. Serum creatinine \> 1.5 x the ULN~ 5. Platelets \< 100,000 cells/\[mm\^3\] (10\^9/L),~ 6. Clinically significant abnormal screening laboratory results as evaluated by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: ACTIVE_COMPARATOR): Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Double-blind placebo administered every week (EW) for 12 weeks
- ABT-122 120 mg (Type: EXPERIMENTAL): Double-blind ABT-122 120 mg administered EW for 12 weeks
- ABT-122 240 mg (Type: EXPERIMENTAL): Double-blind ABT-122 240 mg administered EW for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).